Oncology

The oncology community has been experiencing an unprecedented moment in lung cancer diagnosis and treatment; however, despite significant…

MONARCH 2 was a global, randomised, double-blind, Phase III study of abemaciclib or placebo in combination with fulvestrant in premenopausal…

This meeting took place on 28th September 2019, as part of the Ferring-organised Meet-The-Expert symposium at the European Society of Medical Oncology. Main topic is discussion of new treatment modalities in the management of high-risk, non-muscle invasive bladder cancer.

With a sustained number of new drugs or combination drugs entering standard of care this year, molecular testing should be…

Adding a molecular perspective to the traditional multidisciplinary management of cancer patients is substantially hampering the adoption of precision…

Adjuvant chemotherapy (CT) is commonly recommended to breast cancer patients following surgery. However, not all patients benefit from it, and the…

Cancer of unknown primary (CUP) accounts for 3–5% of all cancers, and prognosis is poor for most patients, with a median survival of 6–9 months…

Dr Birrer presented on the current landscape of platinum-sensitive recurrent ovarian cancer (PSR OC), including USA and European treatment guidelines.